Levothyroxine (T4, Synthroid)
Prescription thyroid hormone medicine for an underactive thyroid; athletes also take it to lose fat, which is not justified without a diagnosis.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Liothyronine vs LevothyroxineDETAILED OVERVIEW
What is Levothyroxine (T4, Synthroid)?
Levothyroxine (Synthroid) is a prescription medicine: a synthetic version of the body's own thyroid hormone (T4). It is the standard treatment for an underactive thyroid and has been approved since 1955. T4 is a prohormone: it is converted in the tissues into the more active hormone (T3), so it acts more slowly and takes weeks to reach its full effect. Athletes also take it to lose fat.
An overdose causes a drug-induced overactive thyroid: palpitations, atrial fibrillation (a heart rhythm disorder), tremor, sweating, weight loss and anxiety; this is especially dangerous in older people and in people with heart disease, and consistently high amounts can also cause bone loss. With blood thinners it increases the risk of bleeding, and in untreated adrenal insufficiency it can trigger an adrenal crisis. WADA allows it only with a documented underactive thyroid; taking it as an athlete without a diagnosis is not legitimate and can count as a rule violation.
Mechanism of action
Thyroid prohormone, peripheral D1/D2 conversion to T3, indirect nuclear TR-α/β agonist
Half-life
~7 days (steady-state ~6 weeks)
Onset
Metabolic-rate increase 1-2 weeks; steady-state 6 weeks
Legal status
FDA + EMA Rx (hypothyroidism), registered in HU + PL. WADA: allowed with documented hypothyroidism diagnosis, off-label cutting is NOT legitimate.
No anecdote collected yet.
Data console
Lab data
Maraka S, Owen RR, Singh Ospina NM . Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial.. Endocrine.
Burch HB, Burman KD, Cooper DS . A 2013 survey of clinical practice patterns in the management of primary hypothyroidism.. J Clin Endocrinol Metab.
Jonklaas J, Bianco AC, Bauer AJ et al. . Guidelines for the treatment of hypothyroidism (ATA). Thyroid. 2014;24(12):1670-1751..
Walsh JP, Shiels L, Lim EM et al. . Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. J Clin Endocrinol Metab. 2003;88(10):4543-4550..
Benvenga S, Carlé A . Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.. Adv Ther.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Iatrogenic hyperthyroidism on overdose: tachycardia, palpitations, atrial fibrillation, heat intolerance, sweating, weight loss, tremor (FDA Synthroid SmPC; most pronounced on supratherapeutic cutting doses).
- Atrial fibrillation and cardiovascular event risk, especially in the elderly and those with pre-existing heart disease; suppressive (TSH <0.1) dosing raises AF incidence 2–3x (Sawin 1994 PMID 8302057).
- Decreased bone density and osteoporosis risk on long-term TSH-suppressive dosing (>200 µg/day, chronic TSH <0.1 mIU/L); DEXA monitoring warranted (Faber 1994 PMID 8112375).
- Central/nervous overdose symptoms: anxiety, irritability, insomnia, restlessness, headache (part of the hyperthyroid syndrome).
- Reduced absorption and dose instability when taken with calcium, iron, PPIs or soy (~30–50% absorption drop); 4-hour separation required.
- Warfarin interaction: T4 potentiates the anticoagulant effect, raising INR and bleeding risk; INR monitoring mandatory.
- In diabetics, the increased metabolic rate can raise insulin and antidiabetic requirements, with possible loss of glucose control.
- Rare cholestasis and <1% ALT elevation; hepatic stress is minimal, though overdose-induced hyperthyroidism is indirectly burdensome (FDA Synthroid SmPC).
Contraindications · 7
- Uncorrected adrenal insufficiency: T4 replacement can precipitate an adrenal crisis; glucocorticoid replacement must come first (absolute contraindication).
- Untreated thyrotoxicosis / hyperthyroidism: T4 further aggravates the thyroid hormone excess (absolute contraindication).
- Recent acute myocardial infarction (<6 months): the increased cardiac workload contraindicates dose titration (absolute contraindication).
- Active tachyarrhythmia (atrial fibrillation, ventricular tachycardia): T4 is arrhythmogenic; cautious titration or deferral is warranted.
- Athlete cutting-cycle off-label use without a documented hypothyroidism diagnosis: medically illegitimate and a potential WADA violation.
- Elderly (>65) and coronary artery disease patients: relative caution, low starting dose and slow (12.5 µg/2 weeks) titration warranted (Stott 2017 TRUST PMID 28121505).
- Chronic TSH-suppressive dosing (>200 µg/day) with osteoporosis or known low bone density: relative contraindication due to bone density loss.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial.
Maraka S, Owen RR, Singh Ospina NM
A 2013 survey of clinical practice patterns in the management of primary hypothyroidism.
Burch HB, Burman KD, Cooper DS
Guidelines for the treatment of hypothyroidism (ATA)
Jonklaas J, Bianco AC, Bauer AJ et al.
Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial
Walsh JP, Shiels L, Lim EM et al.
Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.
Benvenga S, Carlé A
Telegram
Have a question about Levothyroxine (T4, Synthroid)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


